Skip to main content

Table 2 Univariate and multivariate analysis of TMEM176A methylation status with 3Ā year-overall survival (OS) in HCC patients

From: Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma

Clinical factor

3-year OS

Univariate analysis

Multivariate analysis

HR (95% CI)

P value

HR (95% CI)

P value

Age

1.204

0.557

Ā Ā 

ā€ƒ(<ā€‰60 vs. ā‰„ā€‰60Ā years)

(0.649ā€“2.235)

Ā Ā Ā 

Gender

0.869

0.775

Ā Ā 

ā€ƒ(Male vs. female)

(0.331ā€“2.282)

Ā Ā Ā 

TMEM176A

2.388

0.027*

2.370

0.025*

ā€ƒ(Methylation vs. unmethylation)

(1.102ā€“5.175)

Ā 

(1.116ā€“5.034)

Ā 

HBV infection

0.592

0.142

Ā Ā 

ā€ƒ (YES vs. NO)

(0.294ā€“1.191)

Ā Ā Ā 

Liver cirrhosis

1.360

0.401

Ā Ā 

ā€ƒ(Yes vs. no)

(0.664ā€“2.784)

Ā Ā Ā 

Tumor size

1.184

0.670

Ā Ā 

ā€ƒ(ā‰¤ā€‰5Ā cm vs. >ā€‰5Ā cm)

(0.544ā€“2.580)

Ā Ā Ā 

Number of lesions

0.902

0.793

Ā Ā 

ā€ƒ(1 vs. ā‰„ā€‰1)

(0.419ā€“1.944)

Ā Ā Ā 

Differentiation

2.212

0.020*

1.989

0.015*

ā€ƒ(Well or moderate vs. poor)

(1.133ā€“4.320)

Ā 

(1.140ā€“3.470)

Ā 

TNM stage

1.150

0.724

Ā Ā 

ā€ƒ(Stage I + stage II vs. stage III + stage IV)

(0.528ā€“2.505)

Ā Ā Ā 

Lymph node metastasis

1.184

0.670

Ā Ā 

ā€ƒ(Negative vs. positive)

(0.544ā€“2.580)

Ā Ā Ā 

Vessel cancerous embolus

0.444

0.025*

0.441

0.006**

ā€ƒ(Negative vs. positive)

(0.219ā€“0.902)

Ā 

(0.245ā€“0.794)

Ā 
  1. HR hazard ratio
  2. *PĀ <ā€‰0.05; **PĀ <ā€‰0.01